14 unknown. 14 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Unknown 14 |
| Phase 1 | 6 | Unknown 6 |
| Phase 3 | 1 | Unknown 1 |
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CURATE.AI Optimized Modulation for Multiple Myeloma Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 2 / Phase 3 | Unknown | National University Hospital, Singapore | 20 | 2023-09-10 | 2023-09-06 |
| A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide IMM0306, Lenalidomide capsule - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 102 | 2023-05-01 | 2023-05-24 |
| Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Xia Zhongjun | 42 | 2022-07-25 | 2024-06-17 |
| Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM Selinexor, Thalidomide, Lenalidomide - Multiple Myeloma | Phase 2 | Unknown | Juan Du | 90 | 2022-01-27 | 2023-02-27 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma bortezomib, Lenalidomide, Dexamethasone - Myeloma, Newly Diagnosed | Phase 2 | Unknown | Sun Yat-sen University | 50 | 2020-09-25 | 2023-06-18 |
| R2 in the Treatment of Follicular Lymphoma Revlimid - Follicular Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 115 | 2018-11-01 | 2019-07-08 |
| Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis Cyclophosphamide, Dexamethasone, Elotuzumab - Recurrent Primary Amyloidosis | Phase 2 | Unknown | Barbara Ann Karmanos Cancer Institute | 53 | 2017-08-25 | 2023-01-25 |
| R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Academic and Community Cancer Research United | 30 | 2016-05-20 | 2024-07-01 |
| Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome Lenalidomide - Myelodysplastic Syndrome | Phase 2 | Unknown | Ulsan University Hospital | 35 | 2012-08-01 | 2016-05-11 |
| A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma Lenalidomide, Bendamustine, Bio-specimen Retention - Recurrent Adult Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale | 36 | 2011-07-01 | 2015-08-11 |
| Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Revlimid - Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Unknown | Arbeitsgemeinschaft medikamentoese Tumortherapie | 30 | 2010-06-01 | 2015-03-09 |
| Lenalidomide Plus Rituximab (R) in Non Follicular NHL Lenalidomide, Rituximab - Indolent Non Hodgkin Lymphoma | Phase 2 | Unknown | Gruppo Italiano Studio Linfomi | 44 | 2009-04-01 | 2013-04-12 |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Lenalidomide and Rituximab - Chronic Lymphocytic Leukemia, CLL | Phase 2 | Unknown | Chronic Lymphocytic Leukemia Research Consortium | 80 | 2008-02-01 | 2010-09-10 |
Multiple Myeloma (3) · Lymphoma, B-Cell (2) · Hodgkin Disease (1) · Immunoglobulin Light-chain Amyloidosis (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Myelodysplastic Syndromes (1) · Neoplasms, Plasma Cell (1) · Pyloric Stenosis, Hypertrophic (1) · Recurrence (1)
Academic and Community Cancer Research United (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Barbara Ann Karmanos Cancer Institute (1) · Chronic Lymphocytic Leukemia Research Consortium (1) · Gruppo Italiano Studio Linfomi (1) · Huiqiang Huang (1) · ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1) · Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (1) · Juan Du (1) · National University Hospital, Singapore (1) · Ruijin Hospital (1) · Sun Yat-sen University (1) · Ulsan University Hospital (1) · Xia Zhongjun (1)
China (5) · United States (3) · Italy (2) · Austria (1) · Singapore (1) · South Korea (1)
Antonio Pinto, MD (1) · Danelle F James, M.D. (1) · Gaetano Corazzelli, MD (1) · Grzegorz S Nowakowski (1) · Hawk Kim, M.D., Ph.D. (1) · Hua Wang, MD. (1) · Huiqiang Huang, Professor (1) · Jeffrey Zonder, M.D. (1) · Josef Thaler, MD (1) · Juan Du, M.D., Ph.D (1) · Sonja Burgstaller, MD (1) · Stefano Sacchi, MD (1) · Thomas J Kipps, M.D., Ph.D (1) · Zhongjun Xia, Ph.D (1)
2009 (1), 2015 (1), P30CA015083 (1), P30CA022453 (1)